Disease · MONDO_0005306

ankylosing spondylitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ankylosing spondylitis. Diseases, record MONDO_0005306. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005306

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ankylosing spondylitis; Open Targets
Open Targets ID: MONDO_0005306; Open Targets
Other names: Ankylosing Spondylarthritides, Ankylosing Spondyloarthritides, Ankylosing Spondyloarthritis, BECHTEREW DIS, BECHTEREWS DIS, Bechterew Disease, Bechterew's Disease, Bechterews Disease, MARIE STRUEMPELL DIS, Marie Struempell Disease, Rheumatoid Spondylitis, Spondylarthritides, Ankylosing, Spondylarthritis Ankylopoietica, Spondylarthritis, Ankylosing, Spondylitis, Ankylosing, Spondylitis, Rheumatoid, Spondyloarthritides, Ankylosing, Spondyloarthritis, Ankylosing, ankylosing spondylarthritis; Open Targets
Disease Ontology: DOID:7147; Disease Ontology
MeSH: D013167; MeSH
NCI Thesaurus: C84564; NCI Thesaurus
Orphanet: ORPHA:825; Orphanet
Highest stage of its drugs: Approval, for 20 of its 66 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs66

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETANERCEPT	CHEMBL1201572	Protein	Approval	DailyMed and EMA Human Drugs	42	35	33	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	53	31	31	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed and EMA Human Drugs	33	26	26	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Approval	EMA Human Drugs	24	23	23	Drugs and targets
GOLIMUMAB	CHEMBL1201833	Antibody	Approval	DailyMed and EMA Human Drugs	14	12	12	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Approval	DailyMed	48	5	5	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	6	4	3	Drugs and targets
CERTOLIZUMAB PEGOL	CHEMBL1201831	Antibody	Approval	DailyMed	4	3	3	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	3	2	1	Drugs and targets
UPADACITINIB	CHEMBL3622821	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets

1 to 10 of 66

See all 66 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	13	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	10	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
IL17A	Interleukin-17A	5	Interleukin 17A inhibitor	Approval	https://conductscience.org/library/genes/3605	Drugs and targets
TNF	Tumor necrosis factor	5	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	3	Arachidonate 5-lipoxygenase inhibitor	Approval	https://conductscience.org/library/genes/240	Drugs and targets
IL12B	Interleukin-12	3	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	3	Interleukin-23 inhibitor	Phase 3	https://conductscience.org/library/genes/51561	Drugs and targets
JAK1	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials181

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00544557	Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis		1,715	2015-05-12	Ankylosing Spondylitis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01313858	A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)		1,613	2016-11-01	Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing	GOLIMUMAB, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT00760669	An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants		1,061	2013-08-12	Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01208207	A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)	Phase 3	1,015	2015-07-02	Spondylitis, Ankylosing	ETORICOXIB, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT03259074	Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)	Phase 3	859	2023-03-09	Ankylosing Spondylitis	ADALIMUMAB, SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03129100	A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis	Phase 3	773	2021-06-18	Axial Spondyloarthritis	IXEKIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04507763	Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis		763	2021-10-28	Ankylosing Spondylitis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT04169373	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis	Phase 3	734	2022-09-21	Spondyloarthritis	UPADACITINIB	Its record names the disease	ClinicalTrials.gov
NCT04156620	Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA	Phase 3	527	2024-01-23	Ankylosing Spondylitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01583374	Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis	Phase 3	490	2015-03-17	Ankylosing Spondyloarthritis	APREMILAST	Its record names the disease	ClinicalTrials.gov

1 to 10 of 181

See all 181 trials

Comparisons in its trials92

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Any AIN457 vs Placebo Until Week 16: deaths from any cause	1 of 517	0 of 261	778	NCT04156620	Trial comparisons
Any AIN457 vs Placebo Until Week 16: serious adverse events	32 of 517	3 of 261	778	NCT04156620	Trial comparisons
Any AIN457 150 mg vs Placebo: deaths from any cause	0 of 453	0 of 153	606	NCT02896127	Trial comparisons
Any AIN457 150 mg vs Placebo: serious adverse events	33 of 453	3 of 153	606	NCT02896127	Trial comparisons
Secukinumab vs Placebo: The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)	178 of 305	56 of 153	458	NCT02896127	Trial comparisons
Secukinumab vs Placebo: The Proportion of Participants Who Achieve an ASAS40 Response	138 of 294	27 of 146	440	NCT02896127	Trial comparisons
Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria	114 of 229	19 of 115	344	NCT01114880	Trial comparisons
Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS40 Response Criteria	102 of 229	11 of 115	344	NCT01114880	Trial comparisons
Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants With ASAS Partial Remission	50 of 229	4 of 115	344	NCT01114880	Trial comparisons
Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS5/6 Response Criteria	128 of 229	14 of 115	344	NCT01114880	Trial comparisons

1 to 10 of 92

See all 92 comparisons in its trials

Papers from its trials260

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42740449	RESULT	1	PubMed
42386286	RESULT	2	PubMed
42297437	RESULT	2	PubMed
41864490	RESULT	1	PubMed
41555451	RESULT	1	PubMed
41125403	RESULT	2	PubMed
38977276	RESULT	2	PubMed
38834351	RESULT	1	PubMed
38599650	RESULT	1	PubMed
36649967	RESULT	1	PubMed

1 to 10 of 260

See all 260 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005306

GET https://conductscience.org/api/diseases/v1/MONDO_0005306/drugs?page=2

API reference For AI assistants